See Why Coherus Stock Is Rising After Toripalimab Combination Trial In Lung Cancer

• Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) announced positive interim results from CHOICE-01 Phase 3 trial evaluating toripalimab plus chemotherapy for squamous or non-squamous non-small cell lung cancer (NSCLC).

• Related: Toripalimab-Chemo Combo Beat Chemo Alone in Nose & Throat Cancer Trial.

• Total 465 treatment-naive advanced NSCLC patients (220 squamous and 245 non-squamous) were randomized.

• A significant improvement in progression-free survival (PFS) was detected for toripalimab over placebo (hazard ratio (HR)=0.58) with a median PFS of 8.3 vs. 5.6 months.

• The 1-year PFS rates for toripalimab and placebo arms were 32.6% and 13.1%, respectively.

• Toripalimab, in combination with chemotherapy, as compared with chemotherapy alone, resulted in a better objective response rate (squamous: 68.7% vs. 58.9%; non-squamous: 58.6% vs. 26.5%).

• The median duration of response (squamous: 6.9 months vs. 4.2 months; non-squamous: 8.6 months vs. 5.1 months).

• Overall survival (OS) data were not yet mature as of March 7, 2021. There was a trend favoring the toripalimab arm [median OS of 21.0 vs. 16.0 months, HR = 0.81

• On the safety front, the toripalimab combination regime showed a manageable safety profile with no new safety signal observed.

• The incidence of severe/serious adverse events (AEs) was 76.3% in the toripalimab arm vs. 80.1% in the control arm.

• AEs leading to discontinuation of toripalimab or placebo were 12.3% vs. 1.9%, respectively.

• Related content: Benzinga's Full FDA Calendar.

• Price Action: CHRS shares are up 9.97% at $15.55 during the premarket session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Junshi Biosciences, Coherus Receive FDA Breakthrough Therapy Status For Toripalimab In Head & Neck Cancer

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.